By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Adrenergic bronchodilators > Serevent diskus > Salmeterol Dosage
Adrenergic bronchodilators
https://themeditary.com/dosage-information/salmeterol-dosage-15637.html

Salmeterol Dosage

Drug Detail:Serevent diskus (Salmeterol (inhalation) [ sal-mee-ter-all ])

Drug Class: Adrenergic bronchodilators

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Asthma - Maintenance

50 mcg (1 inhalation) orally twice a day, approximately 12 hours apart.

Comments:

  • Reevaluate the therapeutic regimen if a previously effective dosage fails to provide the usual response, as this is often a sign of destabilization of asthma.
  • If symptoms arise in the period between doses, an inhaled, short-acting beta2-­agonist should be taken for immediate relief.

Uses:
  • Treatment of asthma and prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma.

Usual Adult Dose for Bronchospasm Prophylaxis

Prevention of Exercise Induced Bronchospasm (EIB):

  • 50 mcg (1 inhalation) orally at least 30 minutes before exercise

Comments:
  • Protection may last up to 9 hours when used intermittently as needed for prevention.
  • Additional doses should not be taken for 12 hours.
  • Patients receiving twice daily doses for the treatment of asthma should not use additional doses for the prevention of EIB.

Uses:
  • For the prevention of EIB, as a single agent, in patients with no persistent asthma.
  • In patients with persistent asthma use of this drug for the prevention of EIB may be clinically indicated, but the treatment of asthma should include a long-term asthma control medication, such as an inhaled corticosteroid.

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

50 mcg (1 inhalation) orally twice daily, approximately 12 hours apart

Use: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis

Usual Pediatric Dose for Asthma - Maintenance

Less than 4 years: Not approved.

4 years or older: 50 mcg (1 inhalation) orally twice a day, approximately 12 hours apart

Comments:

  • For patients with asthma less than 18 years of age requiring addition of a LABA to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and LABA should be used to ensure adherence with both drugs.
  • If the use of a separate long-term asthma control medication (e.g., inhaled corticosteroid) and LABA is clinically indicated, take appropriate steps to ensure adherence with both treatment components. If adherence cannot be assured, a fixed-dose combination product containing both an inhaled corticosteroid and LABA is recommended.

Uses:
  • Treatment of asthma and prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma.

Usual Pediatric Dose for Bronchospasm Prophylaxis

Prevention of Exercise Induced Bronchospasm:

  • Less than 4 years: Not approved.
  • 4 years or older: 50 mcg (1 inhalation) orally at least 30 minutes before exercise

Comments:
  • Protection may last up to 9 hours in adolescents and up to 12 hours in pediatrics aged 4 to 11 years, when used intermittently as needed for prevention.
  • Additional doses should not be used for 12 hours.
  • Patients receiving twice daily doses for the treatment of asthma should not use additional doses for the prevention of EIB.

Uses:
  • For the prevention of EIB, as a single agent in patients with no persistent asthma
  • In patients with persistent asthma use of this drug for the prevention of EIB may be clinically indicated, but the treatment of asthma should include a long-term asthma control medication, such as an inhaled corticosteroid.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Use with caution.

Precautions

US BOXED WARNINGS:
ASTHMA-RELATED DEATH:

  • Long-acting beta2-adrenergic agonists (LABA), such as this drug, as monotherapy without an inhaled corticosteroid (ICS) increase the risk of asthma-related death.
  • A U.S. trial showed an increase in asthma-related deaths in subjects receiving this drug (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 out of 13,179 subjects on placebo); background ICS use was not required in this study.
  • Large clinical trials se of LABA in fixed-dose combination with ICS do not show significant increases in serious asthma-related events compared with ICS monotherapy. -Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.
  • This drug should be prescribed only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., gradually discontinue this drug) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. -Do not use this drug for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.
  • Available data from controlled clinical trials suggest that LABA monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients.
  • Pediatric and adolescent asthma patients who require a LABA in addition to an ICS, fixed-dose combination ICS and LABA products ensure adherence to both medications; take steps to ensure adherence with both components. If adherence is not assured, a fixed- dose combination ICS and LABA product is recommended.

CONTRAINDICATIONS:
  • Treatment of asthma without concomitant use of an inhaled corticosteroid
  • Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures
  • Severe hypersensitivity to milk proteins

ASTHMA: Safety and efficacy have not been established in patients younger than 4 years.
COPD: Safety and efficacy have not been established in patients younger than 18 years

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For oral inhalation only.
  • This drug should not be used more often or at doses higher than recommended.
  • If a dose is missed, skip that dose and take the next dose at the usual time. Do not take 2
doses at one time.
  • Consult the manufacturer product information for instructions on how to use the inhaler.

Storage requirements:
  • Store in a dry place away from direct heat or sunlight.
  • Store inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use.

General:
  • This drug should only be used with a long-term asthma control medicine, such as an inhaled corticosteroid; it should not be used as the only asthma medicine.
  • Patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids should not use this drug.

Limitation of use:
  • This drug is not indicated for the relief of acute bronchospasm.

Monitoring:
  • Cardiac monitoring is recommended in cases of overdosage.

Patient advice:
  • Patients should seek immediate attention if their condition deteriorates.
  • Dose or frequency should not be increased without consulting the prescribing physician.
  • Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.
  • Concomitant asthma therapy should not be stopped or reduced without medical advice.
  • Other LABA should not be used when using this drug.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by